Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jan 9:14:1260701.
doi: 10.3389/fendo.2023.1260701. eCollection 2023.

Wnt/β-catenin signaling pathway in the tumor progression of adrenocortical carcinoma

Affiliations
Review

Wnt/β-catenin signaling pathway in the tumor progression of adrenocortical carcinoma

Yanghao Tai et al. Front Endocrinol (Lausanne). .

Abstract

Adrenocortical carcinoma (ACC) is an uncommon, aggressive endocrine malignancy with a high rate of recurrence, a poor prognosis, and a propensity for metastasis. Currently, only mitotane has received certification from both the US Food and Drug Administration (FDA) and the European Medicines Agency for the therapy of advanced ACC. However, treatment in the advanced periods of the disorders is ineffective and has serious adverse consequences. Completely surgical excision is the only cure but has failed to effectively improve the survival of advanced patients. The aberrantly activated Wnt/β-catenin pathway is one of the catalysts for adrenocortical carcinogenesis. Research has concentrated on identifying methods that can prevent the stimulation of the Wnt/β-catenin pathway and are safe and advantageous for patients in view of the absence of effective treatments and the frequent alteration of the Wnt/β-catenin pathway in ACC. Comprehending the complex connection between the development of ACC and Wnt/β-catenin signaling is essential for accurate pharmacological targets. In this review, we summarize the potential targets between adrenocortical carcinoma and the Wnt/β-catenin signaling pathway. We analyze the relevant targets of drugs or inhibitors that act on the Wnt pathway. Finally, we provide new insights into how drugs or inhibitors may improve the treatment of ACC.

Keywords: Wnt/beta-catenin; adrenocortical carcinoma; cross talk; therapeutic targets; tumor progression.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Wnt/β-catenin signaling pathway and crosstalk involved in this review.
Figure 2
Figure 2
Epigenetic regulation and Wnt/β-catenin signaling pathway.

Similar articles

Cited by

References

    1. Else T, Kim AC, Sabolch A, Raymond VM, Kandathil A, Caoili EM, et al. . Adrenocortical carcinoma. Endocr. Rev (2014) 35(2):282–326. doi: 10.1210/er.2013-1029 - DOI - PMC - PubMed
    1. Golden SH, Robinson KA, Saldanha I, Anton B, Ladenson PW. Clinical review: Prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review. J Clin Endocrinol Metab (2009) 94(6):1853–78. doi: 10.1210/jc.2008-2291 - DOI - PMC - PubMed
    1. Glenn JA, Else T, Hughes DT, Cohen MS, Jolly S, Giordano TJ, et al. . Longitudinal patterns of recurrence in patients with adrenocortical carcinoma. Surgery (2019) 165(1):186–95. doi: 10.1016/j.surg.2018.04.068 - DOI - PubMed
    1. Baur J, Buntemeyer TO, Megerle F, Deutschbein T, Spitzweg C, Quinkler M, et al. . Outcome after resection of Adrenocortical Carcinoma liver metastases: a retrospective study. BMC Cancer (2017) 17(1):522. doi: 10.1186/s12885-017-3506-z - DOI - PMC - PubMed
    1. Fassnacht M, Kroiss M, Allolio B. Update in adrenocortical carcinoma. J Clin Endocrinol Metab (2013) 98(12):4551–64. doi: 10.1210/jc.2013-3020 - DOI - PubMed

Publication types

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This research is financially supported by the project from Natural Science Research in Shanxi Province (202203021211072).

LinkOut - more resources